Physician profile
Joseph Browder
NPI 1457361222
$10,175.97
in general payments reported to CMS, 2019-2025
46 companies · $851 in 2025
The $851 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,777 · 2020: $1,726 · 2021: $1,817 · 2022: $1,389 · 2023: $1,386 · 2024: $1,231 · 2025: $851.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,466.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,703.13 | 2020-2025 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $970.27 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $669.99 | 2019-2025 | |
| Allergan, INC. | $646.25 | 2019-2020 | |
| Lilly USA, LLC | $612.83 | 2020-2024 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $509.93 | 2019-2024 | Repatha, Otezla |
| Kowa Pharmaceuticals America, INC. | $509.24 | 2019-2025 | Livalo, Seglentis, Zoryve |
| Glaxosmithkline, LLC. | $421.50 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Esperion Therapeutics, INC. | $367.84 | 2020-2024 | Nexletol |
| Arbor Pharmaceuticals, INC. | $347.84 | 2019-2021 | |
| Astellas Pharma US INC | $304.22 | 2019-2023 | Veozah |
| Astrazeneca Pharmaceuticals LP | $287.70 | 2019-2021 | |
| Radius Health, INC. | $253.11 | 2019-2023 | Tymlos |
| Otsuka America Pharmaceutical, INC. | $248.47 | 2023-2024 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $241.52 | 2022 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Browder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.